U.S. Physical Therapy Q2: 8.5% Revenue Growth Didn't Turn Into Profit

Q2 showed strong volume, but weak earnings were the real message

Revenue rose, but profit did not. USPH posted 8.5% revenue growth in Q2, while adjusted EBITDA was essentially flat at $27.0 million versus $26.9 million a year earlier. Net income fell to $9.9 million from $12.4 million, EPS dropped to $0.25 from $0.58, and operating EPS declined from $0.81 to $0.75. That disconnect is the core reason the quarter matters.

Management did not retreat from its outlook and reaffirmed full-year adjusted EBITDA guidance. That shifts the focus to the second half. The bullish view is that Q2 was a messy setup and that new affiliations should help earnings improve once fully integrated. The bearish view is that the company still needs to show stronger operating leverage if revenue is growing while earnings barely move.

High visit volumes did not translate into better PT margins

Demand is visible, earnings power is not

The clearest positive was demand. USPH posted 32.7 visits per clinic per day in Q2, above the prior year's record of 30.6, and the more current measure reached 33.5 average daily visits per clinic. Patient satisfaction also looked strong, with a net promoter score of 93.5 and 95% of patients classified as active promoters. By itself, that is a sign of real customer traction.

Pricing helped, but it was not enough

Management highlighted pricing power, with net revenue per visit reaching $107.59. But the quarter also showed that pricing did not fully offset other pressures. The company noted that Medicare rate cuts and a Michigan payer change weighed on net rates. So the top line could still grow on volume even as payer mix and local rate pressure kept pricing momentum uneven.

Margin compression is the key problem

The bigger issue was profitability in the core PT business. Adjusted PT margins compressed 150 basis points, and adjusted gross margins fell from 21.4% to 19.9%. In simple terms, the clinics handled more patients, but each visit did not generate materially more profit.

That is why the debate remains open. Some cost metrics looked controlled: salaries and related costs per visit rose just 0.7%, and total operating costs per visit declined year over year. Still, the overall margin report suggests that mix and cost absorption were weaker than hoped. For USPH to earn a better multiple, record clinic volumes need to translate into better PT margins, not just more activity.

The next checkpoint is whether the coming integration of 39 hospital-affiliated clinics improves the margin mix or simply adds more high-volume sites to the base.

The second-half test is integration and execution

What has to happen next

The main recovery thesis is straightforward: integrate the acquired clinics quickly and keep overhead from creeping back up. USPH has already completed integration of 31 hospital-affiliated clinics in Q2, with 39 more slated for Q3. If those sites lift blended margins and contribute more predictably, the back half should do more of the heavy lifting.

The guidance makes that expectation concrete. Management kept its full-year adjusted EBITDA guidance at $102 million to $106 million, and the first half produced $47.2 million in adjusted EBITDA. That implies the company still needs roughly $54.8 million to $58.8 million in the second half to hit the target. For context, the company also needs about $56.8 million in H2 to reach the midpoint of guidance. This is not a distant narrative bet; it is a near-term execution test.

AI documentation can help, but it is a supporting lever

The AI effort is not the main driver, but it is still relevant. USPH says its AI-assisted documentation pilot reduced documentation time, helped therapists finish notes before leaving work, and improved patient engagement by allowing clinicians to spend less time on screens. If that translates into better retention and steadier clinic throughput, it can support margins when staffing is tight.

What would confirm or challenge the thesis

The clearest confirmation would be stable corporate expenses alongside better blended PT margins after Q3 integrations. The clearest challenge would be another quarter of strong demand followed by more margin pressure. In this setup, busy clinics are necessary, but they are no longer enough on their own.